Skip to main content
PMC home page
Protein & Cell logoLink to Protein & Cell
. 2011 Aug 6;2(7):523–530. doi: 10.1007/s13238-011-1077-3

Perspectives on the role of mTORC2 in B lymphocyte development, immunity and tumorigenesis

Adam S Lazorchak 1, Bing Su 1,✉
PMCID: PMC4875240  PMID: 21822797

Abstract

Mammalian target of rapamycin complex 2 (mTORC2) is a key downstream mediator of phosphoinositol-3-kinase (PI3K) dependent growth factor signaling. In lymphocytes, mTORC2 has emerged as an important regulator of cell development, homeostasis and immune responses. However, our current understanding of mTORC2 functions and the molecular mechanisms regulating mTORC2 signaling in B and T cells are still largely incomplete. Recent studies have begun to shed light on this important pathway. We have previously reported that mTORC2 mediates growth factor dependent phosphorylation of Akt and facilitates Akt dependent phosphorylation and inactivation of transcription factors FoxO1 and FoxO3a. We have recently explored the functions of mTORC2 in B cells and show that mTORC2 plays a key role in regulating survival and immunoglobulin (Ig) gene recombination of bone marrow B cells through an Akt2-FoxO1 dependent mechanism. Ig recombination is suppressed in proliferating B cells to ensure that DNA double strand breaks are not generated in actively dividing cells. Our results raise the possibility that genetic or pharmacologic inhibition of mTORC2 may promote B cell tumor development as a result of inefficient suppression of Ig recombination in dividing B cells. We also propose a novel strategy to treat cancers based on our recent discovery that mTORC2 regulates Akt protein stability.

Keywords: mTOR, lymphocyte, B cell, cancer, mTORC2, FoxO, Akt, Sin1

References

  1. Amin R.H., Schlissel M.S. Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. Nat Immunol. 2008;9:613–622. doi: 10.1038/ni.1612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baracho G.V., Miletic A.V., Omori S.A., Cato M.H., Rickert R. C. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol. 2011;23:178–183. doi: 10.1016/j.coi.2011.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Calamito M., Juntilla M.M., Thomas M., Northrup D.L., Rathmell J., Birnbaum M.J., Koretzky G., Allman D. Akt1 and Akt2 promote peripheral B-cell maturation and survival. Blood. 2010;115:4043–4050. doi: 10.1182/blood-2009-09-241638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chen J., Limon J.J., Blanc C., Peng S.L., Fruman D.A. Foxo1 regulates marginal zone B-cell development. Eur J Immunol. 2010;40:1890–1896. doi: 10.1002/eji.200939817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chowdhury D., Sen R. Regulation of immunoglobulin heavy-chain gene rearrangements. Immunol Rev. 2004;200:182–196. doi: 10.1111/j.0105-2896.2004.00177.x. [DOI] [PubMed] [Google Scholar]
  6. Dengler H.S., Baracho G.V., Omori S.A., Bruckner S., Arden K.C., Castrillon D.H., DePinho R.A., Rickert R.C. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol. 2008;9:1388–1398. doi: 10.1038/ni.1667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Facchinetti V., Ouyang W., Wei H., Soto N., Lazorchak A., Gould C., Lowry C., Newton A.C., Mao Y., Miao R.Q., et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 2008;27:1932–1943. doi: 10.1038/emboj.2008.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., Shokat K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7:e38. doi: 10.1371/journal.pbio.1000038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Frias M.A., Thoreen C.C., Jaffe J.D., Schroder W., Sculley T., Carr S.A., Sabatini D.M. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol. 2006;16:1865–1870. doi: 10.1016/j.cub.2006.08.001. [DOI] [PubMed] [Google Scholar]
  10. Gingras A.C., Raught B., Sonenberg N. mTOR signaling to translation. Curr Top Microbiol Immunol. 2004;279:169–197. doi: 10.1007/978-3-642-18930-2_11. [DOI] [PubMed] [Google Scholar]
  11. Goldmit M., Bergman Y. Monoallelic gene expression: a repertoire of recurrent themes. Immunol Rev. 2004;200:197–214. doi: 10.1111/j.0105-2896.2004.00158.x. [DOI] [PubMed] [Google Scholar]
  12. Grawunder U., Leu T.M., Schatz D.G., Werner A., Rolink A.G., Melchers F., Winkler T.H. Down-regulation of RAG1 and RAG2 gene expression in preB cells after functional immunoglobulin heavy chain rearrangement. Immunity. 1995;3:601–608. doi: 10.1016/1074-7613(95)90131-0. [DOI] [PubMed] [Google Scholar]
  13. Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci Signal. 2009;2:pe24. doi: 10.1126/scisignal.267pe24. [DOI] [PubMed] [Google Scholar]
  14. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N. Y., Moffat J., Brown M., Fitzgerald K.J., Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006;11:859–871. doi: 10.1016/j.devcel.2006.10.007. [DOI] [PubMed] [Google Scholar]
  15. Harris, T.E., and Lawrence, J.C. Jr. (2003). TOR signaling. Sci STKE 2003, re15. [DOI] [PubMed]
  16. Hasham M.G., Donghia N.M., Coffey E., Maynard J., Snow K.J., Ames J., Wilpan R.Y., He Y., King B.L., Mills K.D. Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination. Nat Immunol. 2010;11:820–826. doi: 10.1038/ni.1909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Herzog S., Hug E., Meixlsperger S., Paik J.H., DePinho R.A., Reth M., Jumaa H. SLP-65 regulates immunoglobulin light chain gene recombination through the PI(3)K-PKB-Foxo pathway. Nat Immunol. 2008;9:623–631. doi: 10.1038/ni.1616. [DOI] [PubMed] [Google Scholar]
  18. Herzog S., Reth M., Jumaa H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol. 2009;9:195–205. doi: 10.1038/nri2491. [DOI] [PubMed] [Google Scholar]
  19. Hietakangas V., Cohen S.M. Re-evaluating AKT regulation: role of TOR complex 2 in tissue growth. Genes Dev. 2007;21:632–637. doi: 10.1101/gad.416307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hoang B., Frost P., Shi Y., Belanger E., Benavides A., Pezeshkpour G., Cappia S., Guglielmelli T., Gera J., Lichtenstein A. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood. 2010;116:4560–4568. doi: 10.1182/blood-2010-05-285726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ikenoue T., Inoki K., Yang Q., Zhou X., Guan K.L. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 2008;27:1919–1931. doi: 10.1038/emboj.2008.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., Su B. SIN1/MIP1 maintains rictormTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125–137. doi: 10.1016/j.cell.2006.08.033. [DOI] [PubMed] [Google Scholar]
  23. Janes M.R., Limon J.J., So L., Chen J., Lim R.J., Chavez M.A., Vu C., Lilly M.B., Mallya S., Ong S.T., et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010;16:205–213. doi: 10.1038/nm.2091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Jung D., Alt F.W. Unraveling V(D)J recombination; insights into gene regulation. Cell. 2004;116:299–311. doi: 10.1016/S0092-8674(04)00039-X. [DOI] [PubMed] [Google Scholar]
  25. Kharas M.G., Deane J.A., Wong S., O’Bosky K.R., Rosenberg N., Witte O.N., Fruman D.A. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood. 2004;103:4268–4275. doi: 10.1182/blood-2003-07-2193. [DOI] [PubMed] [Google Scholar]
  26. Kraus M., Alimzhanov M.B., Rajewsky N., Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117:787–800. doi: 10.1016/j.cell.2004.05.014. [DOI] [PubMed] [Google Scholar]
  27. Lazorchak A.S., Liu D., Facchinetti V., Di Lorenzo A., Sessa W.C., Schatz D.G., Su B. Sin1-mTORC2 suppresses rag and il7r gene expression through Akt2 in B cells. Mol Cell. 2010;39:433–443. doi: 10.1016/j.molcel.2010.07.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Li Z., Dordai D.I., Lee J., Desiderio S. A conserved degradation signal regulates RAG-2 accumulation during cell division and links V(D)J recombination to the cell cycle. Immunity. 1996;5:575–589. doi: 10.1016/S1074-7613(00)80272-1. [DOI] [PubMed] [Google Scholar]
  29. Llorian M., Stamataki Z., Hill S., Turner M., Mårtensson I.L. The PI3K p110delta is required for down-regulation of RAG expression in immature B cells. J Immunol. 2007;178:1981–1985. doi: 10.4049/jimmunol.178.4.1981. [DOI] [PubMed] [Google Scholar]
  30. Mackay F., Figgett W.A., Saulep D., Lepage M., Hibbs M.L. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev. 2010;237:205–225. doi: 10.1111/j.1600-065X.2010.00944.x. [DOI] [PubMed] [Google Scholar]
  31. Malin S., McManus S., Busslinger M. STAT5 in B cell development and leukemia. Curr Opin Immunol. 2010;22:168–176. doi: 10.1016/j.coi.2010.02.004. [DOI] [PubMed] [Google Scholar]
  32. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–1934. doi: 10.1126/science.1075762. [DOI] [PubMed] [Google Scholar]
  33. Oh W.J., Wu C.C., Kim S.J., Facchinetti V., Julien L.A., Finlan M., Roux P.P., Su B., Jacinto E. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. EMBO J. 2010;29:3939–3951. doi: 10.1038/emboj.2010.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Okkenhaug K., Bilancio A., Farjot G., Priddle H., Sancho S., Peskett E., Pearce W., Meek S.E., Salpekar A., Waterfield M.D., et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 2002;297:1031–1034. doi: 10.1126/science.1073560. [DOI] [PubMed] [Google Scholar]
  35. Patke A., Mecklenbräuker I., Erdjument-Bromage H., Tempst P., Tarakhovsky A. BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism. J Exp Med. 2006;203:2551–2562. doi: 10.1084/jem.20060990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Ramadani F., Bolland D.J., Garcon F., Emery J.L., Vanhaesebroeck B., Corcoran A.E., Okkenhaug K. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. [Electronic Resource] Sci Signal. 2010;3:ra60. doi: 10.1126/scisignal.2001104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159–168. doi: 10.1016/j.molcel.2006.03.029. [DOI] [PubMed] [Google Scholar]
  38. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–1101. doi: 10.1126/science.1106148. [DOI] [PubMed] [Google Scholar]
  39. Schlissel M.S. Regulating antigen-receptor gene assembly. Nat Rev Immunol. 2003;3:890–899. doi: 10.1038/nri1225. [DOI] [PubMed] [Google Scholar]
  40. Schlissel M.S., Stanhope-Baker P. Accessibility and the developmental regulation of V(D)J recombination. Semin Immunol. 1997;9:161–170. doi: 10.1006/smim.1997.0066. [DOI] [PubMed] [Google Scholar]
  41. Srinivasan L., Sasaki Y., Calado D.P., Zhang B., Paik J.H., DePinho R.A., Kutok J.L., Kearney J.F., Otipoby K.L., Rajewsky K. PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009;139:573–586. doi: 10.1016/j.cell.2009.08.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Stadanlick J.E., Kaileh M., Karnell F.G., Scholz J.L., Miller J.P., Quinn W.J., 3rd, Brezski R.J., Treml L.S., Jordan K.A., Monroe J. G., et al. Tonic B cell antigen receptor signals supply an NFkappaB substrate for prosurvival BLyS signaling. Nat Immunol. 2008;9:1379–1387. doi: 10.1038/ni.1666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Staszewski O., Baker R.E., Ucher A.J., Martier R., Stavnezer J., Guikema J.E. Activation-induced cytidine deaminase induces reproducible DNA breaks at many non-Ig Loci in activated B cells. Mol Cell. 2011;41:232–242. doi: 10.1016/j.molcel.2011.01.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Tsai A.G., Lu H., Raghavan S.C., Muschen M., Hsieh C.L., Lieber M.R. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell. 2008;135:1130–1142. doi: 10.1016/j.cell.2008.10.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Verkoczy L., Duong B., Skog P., Aït-Azzouzene D., Puri K., Vela J. L., Nemazee D. Basal B cell receptor-directed phosphatidylinositol 3-kinase signaling turns off RAGs and promotes B cell-positive selection. J Immunol. 2007;178:6332–6341. doi: 10.4049/jimmunol.178.10.6332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Wang J.H., Alt F.W., Gostissa M., Datta A., Murphy M., Alimzhanov M.B., Coakley K.M., Rajewsky K., Manis J.P., Yan C.T. Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching. J Exp Med. 2008;205:3079–3090. doi: 10.1084/jem.20082271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wang J.H., Gostissa M., Yan C.T., Goff P., Hickernell T., Hansen E., Difilippantonio S., Wesemann D.R., Zarrin A.A., Rajewsky K., et al. Mechanisms promoting translocations in editing and switching peripheral B cells. Nature. 2009;460:231–236. doi: 10.1038/nature08159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Wicker L.S., Boltz R.C., Jr, Matt V., Nichols E.A., Peterson L.B., Sigal N.H. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol. 1990;20:2277–2283. doi: 10.1002/eji.1830201017. [DOI] [PubMed] [Google Scholar]
  49. Wu Y.-T., Ouyang W., Lazorchak A.S., Liu D., Shen H.-M., Su B. mTOR Complex 2 Targets Akt for Proteasomal Degradation via Phosphorylation at the Hydrophobic Motif. Biol Chem. 2011;286:14190–14198. doi: 10.1074/jbc.M111.219923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell. 2006;124:471–484. doi: 10.1016/j.cell.2006.01.016. [DOI] [PubMed] [Google Scholar]
  51. Yamane A., Resch W., Kuo N., Kuchen S., Li Z., Sun H.W., Robbiani D.F., McBride K., Nussenzweig M.C., Casellas R. Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes. Nat Immunol. 2011;12:62–69. doi: 10.1038/ni.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Zeng Z., Sarbassov D.D., Samudio I.J., Yee K.W.L., Munsell M.F., Ellen Jackson C., Giles F.J., Sabatini D.M., Andreeff M., Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007;109:3509–3512. doi: 10.1182/blood-2006-06-030833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Zhang L., Reynolds T.L., Shan X., Desiderio S. Coupling of V(D)J recombination to the cell cycle suppresses genomic instability and lymphoid tumorigenesis. Immunity. 2011;34:163–174. doi: 10.1016/j.immuni.2011.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Zhu C., Mills K.D., Ferguson D.O., Lee C., Manis J., Fleming J., Gao Y., Morton C.C., Alt F.W. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell. 2002;109:811–821. doi: 10.1016/S0092-8674(02)00770-5. [DOI] [PubMed] [Google Scholar]

Articles from Protein & Cell are provided here courtesy of Oxford University Press

RESOURCES